Ovarian Neoplasm Clinical Trial
Official title:
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery. The MONIALC Study.
This is a single-center, randomized, phase II, non-comparative, single-blind clinical study that will determine whether morphine reduction through intraoperative monitoring by ANI (Analgesia Nociception Index) significantly reduces chronic post-surgical pain at three months after laparotomy for ovarian carcinoma with regard to standard care.
Prior to carrying out the research, the informed consent of the person must be obtained after being informed of the purpose of the research, its conduct and duration, benefits, potential risks and constraints of the study. Before inclusion,all eligibility criteria will be verified, VAS pain score and VAS anxiety will be performed. The surgical procedure for ovarian carcinoma will be performed by laparotomy and the intraoperative monitoring of nociception wil depend of the randomization arm : Intraoperative ANI monitoring of nociception (experimental arm) versus no specific monitoring of nociception (control arm). The total dose of opioids (in micrograms) received by the patients will be recorded at the end of the surgery. VAS pain score will be performed immediately postoperatively and at three months after the intervention. A DN4 questionnaire (neuropathic pain) will be evaluated at three months after the intervention. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
| Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
| Completed |
NCT00248248 -
DOXIL for Consolidation Therapy in Ovarian Cancer.
|
Phase 2 | |
| Recruiting |
NCT05960630 -
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT05059782 -
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
|
N/A | |
| Recruiting |
NCT05752448 -
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
|
N/A | |
| Completed |
NCT05751629 -
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01821833 -
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
|
N/A | |
| Withdrawn |
NCT01477788 -
Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass
|
N/A | |
| Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
| Completed |
NCT04898842 -
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
|
N/A | |
| Terminated |
NCT01374685 -
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
|
||
| Completed |
NCT01139957 -
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
|
||
| Active, not recruiting |
NCT05257408 -
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
|
Phase 3 | |
| Completed |
NCT04573933 -
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
|
||
| Terminated |
NCT02470585 -
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 3 | |
| Completed |
NCT00001898 -
Microarray Analysis for Human Genetic Disease
|
N/A | |
| Recruiting |
NCT04402333 -
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
|
||
| Completed |
NCT00034281 -
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
|
Phase 1 |